Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12188593 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL1714229 | 0.84 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL1714230 | 0.84 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL12028972 | 0.84 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL684461 | 0.84 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL13012357 | 0.83 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL2232983 | 0.83 | MAPT (0.51) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL2232991 | 0.83 | MAPT (0.51) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL2738666 | 0.81 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL4162000 | 0.81 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2966065-A2 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | SLC6A2 3153/4885SLC6A4 2692/4885SLC6A3 2538/4885 |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | SLC6A2 3153/4885SLC6A4 2692/4885SLC6A3 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.